Data / Drug companies / NuCare Pharmaceuticals,Inc.
NuCare Pharmaceuticals,Inc.: 1,369 products in the FDA NDC directory, labeler code 68071
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
NuCare Pharmaceuticals,Inc. (labeler code 68071) lists 1,369 products in the FDA National Drug Code Directory, covering 304 finished drugs by generic name. By type: 1,291 prescription drugs, 78 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on December 15, 2025.
The request: Watch NuCare Pharmaceuticals,Inc. (FDA labeler code 68071): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68071
- Products in commercial distribution
- 1,369
- Packages
- 2,367
- Finished drugs by generic name
- 304
- Prescription products
- 1,291
- Over the counter products
- 78
- Controlled substance products
- Schedule II 13, Schedule III 15, Schedule IV 56, Schedule V 2
- Started marketing in the last 12 months
- 2
- Products with a marketing end date set
- 12
- Earliest marketing start
- January 12, 1973
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 1,281 | 93.6% |
| Over the counter monograph drugs | 53 | 3.9% |
| Authorized generics (NDA) | 13 | 0.9% |
| New drug applications (NDA) | 12 | 0.9% |
| Other unapproved drugs | 9 | 0.7% |
| Biologics (BLA) | 1 | 0.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 1,291 | 94.3% |
| Over the counter drugs | 78 | 5.7% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 524 | 38.3% |
| Tablet, film coated | 336 | 24.5% |
| Capsule | 140 | 10.2% |
| Cream | 51 | 3.7% |
| Powder, for suspension | 34 | 2.5% |
| Solution | 30 | 2.2% |
| Capsule, delayed release | 28 | 2% |
| Tablet, extended release | 25 | 1.8% |
| Tablet, coated | 25 | 1.8% |
| Solution/ drops | 23 | 1.7% |
| Ointment | 19 | 1.4% |
| Tablet, delayed release | 17 | 1.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Rosuvastatin Calcium | 68071-5333 | Tablet | Generic drugs (ANDA) | December 15, 2025 |
| Ketoconazole | 68071-5294 | Shampoo, suspension | Generic drugs (ANDA) | December 1, 2025 |
| Dexamethasone | 68071-3962 | Tablet | Generic drugs (ANDA) | October 15, 2025 |
| Metformin hydrochloride | 68071-5306 | Tablet, film coated | Generic drugs (ANDA) | August 25, 2025 |
| Fluticasone propionate | 68071-3949 | Spray | Generic drugs (ANDA) | June 5, 2025 |
| Desvenlafaxine | 68071-5332 | Tablet, extended release | Generic drugs (ANDA) | May 2, 2025 |
| Glipizide | 68071-5326 | Tablet | Generic drugs (ANDA) | May 1, 2025 |
| Diclofenac sodium | 68071-5319 | Tablet, delayed release | Generic drugs (ANDA) | April 17, 2025 |
| Levothyroxine sodium | 68071-5336 | Tablet | Generic drugs (ANDA) | April 8, 2025 |
| Levothyroxine sodium | 68071-5335 | Tablet | Generic drugs (ANDA) | April 8, 2025 |
| Levothyroxine sodium | 68071-3996 | Tablet | Generic drugs (ANDA) | April 8, 2025 |
| Levothyroxine sodium | 68071-3887 | Tablet | Generic drugs (ANDA) | April 8, 2025 |
| Hydrocortisone with Aloe | 68071-5305 | Cream | Over the counter monograph drugs | March 26, 2025 |
| Pravastatin sodium | 68071-3895 | Tablet | Generic drugs (ANDA) | February 27, 2025 |
| Metoclopramide | 68071-3924 | Tablet | Generic drugs (ANDA) | February 12, 2025 |
| Metoclopramide | 68071-5314 | Tablet | Generic drugs (ANDA) | January 9, 2025 |
| Metoclopramide | 68071-5303 | Tablet | Generic drugs (ANDA) | January 9, 2025 |
| Diphenhydramine HCl | 68071-3877 | Capsule | Over the counter monograph drugs | December 6, 2024 |
| Loperamide hydrochloride | 68071-5331 | Capsule | Generic drugs (ANDA) | December 1, 2024 |
| Dicyclomine hydrochloride | 68071-5298 | Tablet | Generic drugs (ANDA) | November 15, 2024 |
| Extra Strength Acetaminophen | 68071-3907 | Tablet | Over the counter monograph drugs | November 1, 2024 |
| Atorvastatin calcium | 68071-5344 | Tablet, film coated | Generic drugs (ANDA) | October 1, 2024 |
| Atorvastatin calcium | 68071-5334 | Tablet, film coated | Generic drugs (ANDA) | October 1, 2024 |
| Atorvastatin calcium | 68071-3874 | Tablet, film coated | Generic drugs (ANDA) | October 1, 2024 |
| Propranolol Hydrochloride | 68071-5321 | Tablet | Generic drugs (ANDA) | September 19, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.